secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0000950170-25-104986
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio reports Q2 net loss of $5.1M; 4-year PFS milestone in glioblastoma trial
-------------------------------------------------------------------------------

- Net loss $5.1M ($1.24/sh) vs $8.6M ($5.51/sh) in Q2 2024; R&D expenses down to $2.5M from $5.2M.
- Cash $13.2M as of June 30, 2025 (up from $10.2M year ago); runway extended into June 2026.
- INB-200 trial patient surpasses 4 years without progression; mPFS 16.1 months for multi-dose patients (standard of care 6.9 months).
- Preclinical data at ASGCT 2025: INB-619 achieves complete B cell depletion in lupus samples without significant inflammatory cytokines.
- Received Host Region USA East Abstract Award at ISCT 2025 for DeltEx manufacturing platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000095017025104986/0000950170-25-104986-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000095017025104986/inab-20250807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-104986

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer